IP Library Granted Patent US 6,982,285
Granted Patent B2
US 6,982,285 · App. 10/348,717 · Granted Jan 3, 2006

Control of parasites attached to skin of fish

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,982,285
App. No.
10/348,717
Granted
Jan 3, 2006
Kind
B2
Abstract

A method of successfully controlling sea lice in commercial fish farming, in an efficient and environmentally friendly way, with the compounds named in claim 1 , preferably by injection, and a method of automating this type of control, are described.

Claims (10)

1. A process for the preparation of a composition for controlling fish parasites, comprising 0.1 to 99% by weight of a compound of formula (I)

or of one of its physiologically tolerable acid addition salts, wherein X is halogen; X 1 is hydrogen or halogen X 2 , is hydrogen or halogen; —O—Y is in position 3, and Y represents the group

Y 1 is hydrogen or halogen; Y 2 is hydrogen or halogen; Y 3 is hydrogen or halogen; Z 1 is hydrogen or C 1 -C 3 -alkyl; Z 2 is hydrogen or C 1 -C 3 -alkyl and U is hydrogen or halogen; and 99.9 to 1% by weight of an excipient that is physiologically tolerated by fish.

2. The process according to claim 1 wherein the process further comprises mixing 0.1 to 25% by weight of a surfactant that is non-toxic to fish.

3. A composition in the form of an olly injectable suspension, comprising a compound of the formula (I)

or of one of its physiologically tolerable acid addition salts, wherein X is halogen; X 1 is hydrogen or halogen; X 2 is hydrogen or halogen; —O—Y is in position 3, and Y represents the group

Y 1 is hydrogen or halogen; Y 2 is hydrogen or halogen; Y 3 is hydrogen or halogen; Z 1 is hydrogen or C 1 -C 3 -alkyl; Z 2 is hydrogen or C 1 -C 3 -alkyl; and U is hydrogen or halogen and a lipophilic solvent.

4. A composition according to claim 3 , further comprising an excipient that is physiologically tolerated by fish.

5. A composition in the form of an oily injectable suspension, comprising 1-[4-chloro-3-(3-chloro-5-trifluoromethyl-2-pyridyloxy)]-3-(2.6-difluorobenzoyl)urea and a lipophilic solvent.

6. A composition according to claim 5 , further comprising an excipient that is physiologically tolerated by fish.

Assignments (5)
ASSIGNMENT OF SECURITY INTEREST IN PATENT RIGHTS, RECORDED ON AUGUST 3, 2020, AT REEL/FRAME 053388/0967 Recorded Dec 3, 2025
From: GOLDMAN SACHS BANK USA, AS RETIRING COLLATERAL AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 073816/0021 →
SECURITY INTEREST Recorded Aug 3, 2020
From: ELANCO US INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 053388/0967 →
CHANGE OF NAME Recorded Nov 2, 2015
From: NOVARTIS ANIMAL HEALTH US, INC.
To: ELANCO US INC.
Reel/Frame 037020/0517 →
CORRECT AN ERROR MADE IN A PREVIOUSLY RECORDED DOCUMENT THAT ERRONEOUSLY AFFECTS THE IDENTIFIED PATENT Recorded Apr 10, 2015
From: NOVARTIS ANIMAL HEALTH US, INC.
To: NOVARTIS ANIMAL HEALTH US, INC.
Reel/Frame 035399/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2015
From: NOVARTIS AG
To: NOVARTIS TIERGESUNDHEIT AG
Reel/Frame 034925/0949 →